{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T08:01:49Z","timestamp":1783238509498,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-024-11253-x","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:07:39Z","timestamp":1734635259000},"page":"3181-3191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic value of early response in predicting survival in hepatocellular carcinoma patients treated with selective internal radiation therapy"],"prefix":"10.1007","volume":"35","author":[{"given":"Michel","family":"Dupuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axelle","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Vilgrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Bando Delaunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachida","family":"Lebtahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Bouattour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6081-1663","authenticated-orcid":false,"given":"Jules","family":"Gr\u00e9gory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"11253_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer Statistics, 2024. Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","DOI":"10.3322\/caac.21820"},{"key":"11253_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/jcm8010055","volume":"8","author":"A Saini","year":"2019","unstructured":"Saini A, Wallace A, Alzubaidi S et al (2019) History and evolution of Yttrium-90 radioembolization for hepatocellular carcinoma. J Clin Med 8:55. https:\/\/doi.org\/10.3390\/jcm8010055","journal-title":"J Clin Med"},{"key":"11253_CR3","doi-asserted-by":"publisher","first-page":"v59","DOI":"10.1093\/annonc\/mdq166","volume":"21","author":"S Jelic","year":"2010","unstructured":"Jelic S, Sotiropoulos GC (2010) Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v59\u2013v64. https:\/\/doi.org\/10.1093\/annonc\/mdq166","journal-title":"Ann Oncol"},{"key":"11253_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM et al (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"key":"11253_CR5","doi-asserted-by":"publisher","unstructured":"Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"11253_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"11253_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/cncr.24050","volume":"115","author":"A Forner","year":"2009","unstructured":"Forner A, Ayuso C, Varela M et al (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. Cancer 115:616\u2013623. https:\/\/doi.org\/10.1002\/cncr.24050","journal-title":"Cancer"},{"key":"11253_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jvir.2008.05.002","volume":"19","author":"TK Rhee","year":"2008","unstructured":"Rhee TK, Naik NK, Deng J et al (2008) Tumor response after Yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Intervent Radiol 19:1180\u20131186. https:\/\/doi.org\/10.1016\/j.jvir.2008.05.002","journal-title":"J Vasc Intervent Radiol"},{"key":"11253_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jvir.2014.01.025","volume":"25","author":"CS Reiner","year":"2014","unstructured":"Reiner CS, Morsbach F, Sah B-R et al (2014) Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion. J Vasc Inter Radiol 25:747\u2013759. https:\/\/doi.org\/10.1016\/j.jvir.2014.01.025","journal-title":"J Vasc Inter Radiol"},{"key":"11253_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1754-9485.2011.02241.x","volume":"55","author":"L Bester","year":"2011","unstructured":"Bester L, Hobbins PG, Wang S, Salem R (2011) Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer. J Med Imaging Radiat Oncol 55:111\u2013118. https:\/\/doi.org\/10.1111\/j.1754-9485.2011.02241.x","journal-title":"J Med Imaging Radiat Oncol"},{"key":"11253_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"key":"11253_CR12","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753\u20131759. https:\/\/doi.org\/10.1200\/JCO.2006.07.3049","journal-title":"JCO"},{"key":"11253_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.5009\/gnl20324","volume":"14","author":"BH Kim","year":"2020","unstructured":"Kim BH (2020) Selecting the right tool for the right job: which response criteria better predicts survival of patients treated with transarterial radioembolization? Gut Liver 14:671\u2013672. https:\/\/doi.org\/10.5009\/gnl20324","journal-title":"Gut Liver"},{"key":"11253_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/curroncol28010095","volume":"28","author":"Y Kim","year":"2021","unstructured":"Kim Y, Lee JS, Lee HW et al (2021) Predictors of complete response in patients with hepatocellular carcinoma treated with trans-arterial radioembolization. Curr Oncol 28:965\u2013977. https:\/\/doi.org\/10.3390\/curroncol28010095","journal-title":"Curr Oncol"},{"key":"11253_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5009\/gnl19197","volume":"14","author":"JS Lee","year":"2020","unstructured":"Lee JS, Choi HJ, Kim BK et al (2020) The Modified Response Evaluation Criteria in Solid Tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial radioembolization. Gut Liver 14:765\u2013774. https:\/\/doi.org\/10.5009\/gnl19197","journal-title":"Gut Liver"},{"key":"11253_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100100","volume":"2","author":"J Gregory","year":"2020","unstructured":"Gregory J, Dioguardi Burgio M, Corrias G et al (2020) Evaluation of liver tumour response by imaging. JHEP Rep. 2:100100. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100100","journal-title":"JHEP Rep."},{"key":"11253_CR17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/hep.27915","volume":"62","author":"AR Seyal","year":"2015","unstructured":"Seyal AR, Gonzalez\u2010Guindalini FD, Arslanoglu A et al (2015) Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 62:1111\u20131121. https:\/\/doi.org\/10.1002\/hep.27915","journal-title":"Hepatology"},{"key":"11253_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver Imaging Reporting and Data System (LI-RADS) Version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816\u2013830. https:\/\/doi.org\/10.1148\/radiol.2018181494","journal-title":"Radiology"},{"key":"11253_CR19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3348\/kjr.2020.1159","volume":"22","author":"J Yoon","year":"2021","unstructured":"Yoon J, Lee S, Shin J et al (2021) LI-RADS version 2018 treatment response algorithm: diagnostic performance after transarterial radioembolization for hepatocellular carcinoma. Korean J Radiol 22:1279\u20131288. https:\/\/doi.org\/10.3348\/kjr.2020.1159","journal-title":"Korean J Radio"},{"key":"11253_CR20","doi-asserted-by":"publisher","unstructured":"King MJ, Tong A, Dane B et al (2020) Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. Eur J Radiol 133. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109351","DOI":"10.1016\/j.ejrad.2020.109351"},{"key":"11253_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358\u2013380. https:\/\/doi.org\/10.1002\/hep.29086","journal-title":"Hepatology"},{"key":"11253_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1159\/000439101","volume":"33","author":"M Kudo","year":"2015","unstructured":"Kudo M, Kitano M, Sakurai T, Nishida N (2015) General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. Dig Dis 33:765\u2013770. https:\/\/doi.org\/10.1159\/000439101","journal-title":"Dig Dis"},{"key":"11253_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","volume":"296","author":"A-L Hermann","year":"2020","unstructured":"Hermann A-L, Dieudonn\u00e9 A, Ronot M et al (2020) Relationship of tumor radiation\u2013absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH Study. Radiology 296:673\u2013684. https:\/\/doi.org\/10.1148\/radiol.2020191606","journal-title":"Radiology"},{"key":"11253_CR24","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1007\/s00330-019-06623-9","volume":"30","author":"SW Kim","year":"2020","unstructured":"Kim SW, Joo I, Kim H-C et al (2020) LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 30:2861\u20132870. https:\/\/doi.org\/10.1007\/s00330-019-06623-9","journal-title":"Eur Radio"},{"key":"11253_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00330-019-06376-5","volume":"30","author":"N Seo","year":"2020","unstructured":"Seo N, Kim MS, Park M-S et al (2020) Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017. Eur Radiol 30:261\u2013271. https:\/\/doi.org\/10.1007\/s00330-019-06376-5","journal-title":"Eur Radiol"},{"key":"11253_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.diii.2018.07.005","volume":"100","author":"S Young","year":"2019","unstructured":"Young S, Taylor A, Golzarian J et al (2019) Clinical utility of one month imaging following selective internal radiation therapy. Diagn Inter Imaging 100:39\u201346. https:\/\/doi.org\/10.1016\/j.diii.2018.07.005","journal-title":"Diagn Inter Imaging"},{"key":"11253_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.diii.2019.05.006","volume":"100","author":"J Delicque","year":"2019","unstructured":"Delicque J, Hermida M, Piron L et al (2019) Intra arterial treatment of hepatocellular carcinoma: comparison of MELD score variations between radio-embolization and chemo-embolization. Diagn Inter Imaging 100:689\u2013697. https:\/\/doi.org\/10.1016\/j.diii.2019.05.006","journal-title":"Diagn Inter Imaging"},{"key":"11253_CR28","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S et al (2016) Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151:1155\u20131163.e2. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.029","journal-title":"Gastroenterology"},{"key":"11253_CR29","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.23944","volume":"52","author":"P Hilgard","year":"2010","unstructured":"Hilgard P, Hamami M, Fouly AE et al (2010) Radioembolization with Yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52:1741\u20131749. https:\/\/doi.org\/10.1002\/hep.23944","journal-title":"Hepatology"},{"key":"11253_CR30","doi-asserted-by":"publisher","unstructured":"Salem R, Mazzaferro V, Sangro B (2013) Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges and clinical perspectives. Hepatology https:\/\/doi.org\/10.1002\/hep.26382","DOI":"10.1002\/hep.26382"},{"key":"11253_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.diii.2020.09.004","volume":"102","author":"M Ghosn","year":"2021","unstructured":"Ghosn M, Derbel H, Kharrat R et al (2021) Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Inter Imaging 102:35\u201344. https:\/\/doi.org\/10.1016\/j.diii.2020.09.004","journal-title":"Diagn Inter Imaging"},{"key":"11253_CR32","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan S-B et al (2018) SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 36:1913\u20131921. https:\/\/doi.org\/10.1200\/JCO.2017.76.0892","journal-title":"J Clin Oncol"},{"key":"11253_CR33","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1200\/JCO.2011.38.4206","volume":"29","author":"M Buyse","year":"2011","unstructured":"Buyse M, Sargent DJ, Saad ED (2011) Survival is not a good outcome for randomized trials with effective subsequent therapies. J Clin Oncol 29:4719\u20134720. https:\/\/doi.org\/10.1200\/JCO.2011.38.4206","journal-title":"JCO"},{"key":"11253_CR34","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, Garin E, Maccauro M et al (2022) A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging 49:3340\u20133352. https:\/\/doi.org\/10.1007\/s00259-022-05774-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11253_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B et al (2021) Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 6:17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11253_CR36","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00259-022-06002-5","volume":"50","author":"J Gregory","year":"2023","unstructured":"Gregory J, Tselikas L, Allimant C et al (2023) Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study. Eur J Nucl Med Mol Imaging 50:921\u2013928. https:\/\/doi.org\/10.1007\/s00259-022-06002-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11253_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","volume":"50","author":"R Salem","year":"2023","unstructured":"Salem R, Padia SA, Lam M et al (2023) Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 50:328\u2013343. https:\/\/doi.org\/10.1007\/s00259-022-05956-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11253_CR38","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E et al (2021) Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 74:2342\u20132352. https:\/\/doi.org\/10.1002\/hep.31819","journal-title":"Hepatology"},{"key":"11253_CR39","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1007\/s00330-022-08585-x","volume":"32","author":"W L\u00fcdemann","year":"2022","unstructured":"L\u00fcdemann W, Kahn J, Pustelnik D et al (2022) Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection. Eur Radiol 32:4687\u20134698. https:\/\/doi.org\/10.1007\/s00330-022-08585-x","journal-title":"Eur Radiol"},{"key":"11253_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","volume":"67","author":"J Calderaro","year":"2017","unstructured":"Calderaro J, Couchy G, Imbeaud S et al (2017) Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 67:727\u2013738. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.014","journal-title":"J Hepatol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-11253-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:08:18Z","timestamp":1747307298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-11253-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["11253"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-11253-x","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Jules Gr\u00e9gory.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"M.R. is a member of the Scientific Editorial Board for European Radiology (section: Magnetic Resonance). As such, they did not participate in the selection nor review processes for this article. The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors, Axelle Dupont, has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}